Drug Trial Radar · NCT04810637
A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19
Last checked: Nov 19, 2026Latest source record: Mar 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
210
Planned (sponsor's estimate)
Start
Nov 1, 2020
Primary completion
Jun 2021
Study completion Sep 2021
Sponsor
- Lead sponsor
- PT Kalbe Genexine BiologicsIndustry
- Sponsor type
- Industry
- Collaborators
- Genexine, Inc.
- First posted
- Mar 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 prospective, randomized, placebo-controlled, double-blinded, parallel group, single administration, multi-center study to assess the safety and efficacy of efineptakin alfa single treatment compared to placebo in elderly participants (adults ≥50years) with asymptomatic or mild COVID-19
Conditions
- Covid19
Interventions
GX-I7Drug
Recombinant human interleukin-7 hybrid Fc
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose findingTime frame: 9 weeks
- Absolute lymphocyte count (ALC)Time frame: 9 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Mitra Keluarga Kelapa Gading
Jakarta Pusat, Indonesia · Recruiting
Mitra Keluarga Kemayoran
Jakarta Pusat, Indonesia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.